Biovitrum, Glaxo End Obesity Alliance For Serotonin-Focused Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Glaxo returns rights on serotonin receptor agonists to the Swedish company, which will not develop them further for obesity.